Latest Market Entry News

Canyon Resources has secured a significant credit facility and advanced key contracts, setting the stage for production and first bauxite shipments from its Minim Martap project in early 2026.

Firebird Metals has reported promising lab-scale results for its lithium manganese iron phosphate cathode material, showing a significant energy density improvement over standard LFP. The company is moving towards pilot-scale production and global commercialisation.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Jayride Group launches a new B2B SaaS platform aimed at transforming ground transportation with integrated payments, fleet management, and AI tools, promising higher margins and scalable growth.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Clarity Pharmaceuticals has partnered with SpectronRx to manufacture and distribute its lead prostate cancer diagnostic, Cu-64 SAR-bisPSMA, at commercial scale across the US. This agreement sets the stage for a seamless launch pending FDA approval.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Impact Minerals Limited has released a robust Preliminary Feasibility Study for its Lake Hope High Purity Alumina project, revealing strong economics and a maiden Ore Reserve. The company is advancing towards a Definitive Feasibility Study and pilot plant construction, positioning itself for low-cost, low-carbon HPA production.